Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2025)
Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies. The high cost of oncology drugs-exceeding $150 billion globally in 2022-and the slow pace of new drug approvals further complicate timely patient access to effective therapies. In this context, drug repurposing-the strategy of identifying new therapeutic uses for existing drugs-has emerged as a promising approach to accelerate cancer treatment development while reducing costs and safety risks. Among repurposed candidates , antiparasitic drugs such as fenbendazole, mebendazole, and ivermectin have attracted considerable...
